Evidence map›Paper›PMID 27812861›Full record

ReviewCurrent oncology reports2016

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).

Jorge García, Lucia Santomé, Urbano Anido, Ovidio Fernández-Calvo, Javier Afonso-Afonso, Martín Lázaro, Ana Medina, Sergio Vázquez Estévez

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jorge GarcíaDepartment of Oncology, Santiago University Hospital, Santiago, Spain.
Lucia SantoméDepartment of Oncology, POVISA Hospital, Vigo, Spain.
Urbano AnidoDepartment of Oncology, Santiago University Hospital, Santiago, Spain.
Ovidio Fernández-CalvoDepartment of Oncology, Ourense University Hospital, Ourense, Spain.
Javier Afonso-AfonsoDepartment of Oncology, Ferrol University Hospital, Ferrol, Spain.
Martín LázaroDepartment of Oncology, Álvaro Cunqueiro Hospital, Vigo, Spain.
Ana MedinaDepartment of Oncology, Galicia Oncology Center, A Coruña, Spain.
Sergio Vázquez EstévezDepartment of Oncology, Lucus Augusti University Hospital, Lugo, Spain. sergio.vazquez.estevez@sergas.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Once metastatic bladder cancer has progressed to first-line treatment, the number of therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II trials, including taxanes, vinflunine (VFL) is the only one shown to increase overall survival in a phase III trial. In addition to its efficacy, VFL is safe in special population groups. Despite this, the prognosis for these patients remains poor, and more effective therapies need to be developed. Agents acting on new therapeutic targets as well as biomarkers to aid matching patients to specific treatments are currently under evaluation. In this regard, immunotherapy is showing promising results. In this article, a critical review of current treatments and future prospects is made, and therapy recommendations are made based on existing scientific evidence.

Indexed as

Antineoplastic AgentsClinical Trials as TopicHumansMolecular Targeted TherapyPractice Guidelines as TopicPrognosisUrinary Bladder NeoplasmsAntineoplastic AgentsBladder cancerPrognostic factorsSecond-line treatmentVinflunine

Identifiers

PMID27812861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.